MarketLens

Has Alumis's Envudeucitinib Redefined Psoriasis Treatment

7 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

Already a Pro member? Log in

SHARE THIS ON:

Has Abbott Laboratories Just Redefined Its Future with Exact Sciences

8 months ago

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

8 months ago

What Does Stopping GLP-1 Treatment Really Mean for Your Heart

7 months ago

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

6 months ago

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Alumis reported new Phase 3 data showing envudeucitinib rapidly and durably improved scalp, itch, and quality-of-life measures in moderate-to-severe plaque psoriasis, building on 54% PASI 100 at Week ...

ALMS

Stock News•1 months ago

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

Takeda's zasocitinib NDA for moderate-to-severe plaque psoriasis was accepted by the FDA under Priority Review, potentially accelerating U.S. approval and redefining oral treatment expectations.

TAK

Stock News•3 months ago

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

NextCure and Avere Therapeutics will merge to advance AVR-001, an oral IL-23 therapy. Phase 1b psoriasis data supports its potential as a once-weekly treatment.

NXTC